HC-5404-Fu

HC-5404-Fu is a PERK inhibitor with an antitumor activity. HC-5404-Fu inhibits endoplasmic reticulum stress response signalling. HC-5404-Fu sensitizes renal cell carcinoma cells to vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors (TKIs) . HC-5404-Fu is promising for research of renal cell carcinoma, gastric cancer, metastatic breast cancer, small cell lung cancer, and other solid tumors[1][2][3].

Product Specifications

CAS Number

[3034479-99-4]

UNSPSC

12352005

Target

PERK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/hc-5404-fu.html

Purity

98.92

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C)NC(C1=CC(C2=CC=C(C=C2C)NC([C@@H](C3=CC(F)=CC(F)=C3)O)=O)=CN=C1N)=O.O=C(O)/C=C/C(O)=O.[1/2]

Molecular Formula

C24H24F2N4O3.1/2C4H4O4

Molecular Weight

512.51

References & Citations

[1]Lines CL, et al. The integrated stress response in cancer progression: a force for plasticity and resistance. Front Oncol. 2023 Aug 3;13:1206561. |[2]Al-Rawi DH, et al. Targeting chromosomal instability in patients with cancer. Nat Rev Clin Oncol. 2024 Sep;21 (9) :645-659.|[3]Al Azzani M, et al. Phytochemical-mediated modulation of autophagy and endoplasmic reticulum stress as a cancer therapeutic approach. Phytother Res. 2024 Jul 3.